meta
|
evidence
oncology
Living systematic review and meta-analysis
locally advanced NSCLC - maintenance (M)
laNSCLC - M - all population
1
laNSCLC - M - EGFR mutant
<span style="margin-left: 0em;">immune chekpoint inhibitors</span>
<span style="margin-left: 1em;">anti-PD-(L)1</span>
<span style="margin-left: 2em;">durvalumab based treatment</span>
<span style="margin-left: 3em;">durvalumab alone <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span>
<span style="margin-left: 0em;">non active control</span>
<span style="margin-left: 1em;">placebo <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span>
Select endpoint...
deaths (OS) (1)
progression or deaths (PFS) (1)
objective responses (ORR) (1)
deaths (OS) (extension) (1)
DOR (1)
PFS (extension) (1)
DOR (extension) (1)
AE (any grade) (1)
TRAE (any grade) (1)
AE leading to treatment discontinuation (any grade) (1)
TRAE (grade 3-4) (1)
AE (grade 3-4) (1)
TRAE leading to death (grade 5) (1)
SAE (any grade) (1)
AE leading to death (grade 5) (1)
Diarrhoea TRAE (grade 3-4) (1)
Pruritus TRAE (grade 3-4) (1)
Rash TRAE (grade 3-4) (1)
Hypothyroidism TRAE (grade 3-4) (1)
Hyperthyroidism TRAE (grade 3-4) (1)
Nausea TRAE (grade 3-4) (1)
Decreased appetite TRAE (grade 3-4) (1)
Asthenia TRAE (grade 3-4) (1)
Dyspnoea TRAE (grade 3-4) (1)
Pneumonitis TRAE (grade 3-4) (1)
Cough TRAE (grade 3-4) (1)
Dyspnoea AE (grade 3-4) (1)
Cough AE (grade 3-4) (1)
Diarrhoea AE (grade 3-4) (1)
Rash AE (grade 3-4) (1)
Pyrexia AE (grade 3-4) (1)
Pruritus AE (grade 3-4) (1)
Nausea AE (grade 3-4) (1)
Constipation AE (grade 3-4) (1)
Fatigue AE (grade 3-4) (1)
Asthenia AE (grade 3-4) (1)
Headache AE (grade 3-4) (1)
Back pain AE (grade 3-4) (1)
Hypothyroidism AE (grade 3-4) (1)
Arthralgia AE (grade 3-4) (1)
Anaemia AE (grade 3-4) (1)
Pneumonitis AE (grade 3-4) (1)
Decreased appetite AE (grade 3-4) (1)
Pneumonia AE (grade 3-4) (1)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
insufficient data
Evidence network for deaths (OS)
1
PACIFIC, 2017
placebo
durvalumab alone
direct evidence
network meta-analysis
comet plot
result box
odds ratio
A
B
0.5
1.5
1.0
odds ratio for A vs. B
and half 95% CI
T
vs.
C
placebo
durvalumab alone
placebo
---
NA
durvalumab alone
NA
---
pathologies: 195 - treatments: 374
result logic
×
Study list
